

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/061452 A1(51) International Patent Classification⁷: **C07D 205/08**,
A61K 31/397, A61P 3/06, 9/10, 25/28(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
S-151 85 Södertälje (SE).(21) International Application Number:
PCT/SE2004/001960(22) International Filing Date:
21 December 2004 (21.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0329780.1 23 December 2003 (23.12.2003) GB
0401907-1 21 July 2004 (21.07.2004) SE
0402785-0 15 November 2004 (15.11.2004) SE(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ALENFALK, Susanne** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **DAHLSTRÖM, Mikael** [FI/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **HUNEGNAW, Fana** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **KARLSSON, Staffan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LEMURELL, Malin** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LINDQVIST, Ann-Margret** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **SKJÄRET, Tore** [NO/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **STARKE, Ingemar** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

Published:

— with international search report

(48) Date of publication of this corrected version:


6 April 2006

(15) Information about Correction:

see PCT Gazette No. 14/2006 of 6 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY



(57) Abstract: Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

WO 2005/061452 A1